


Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Complete if Known

Application Number 10/071861
Filing Date February 7, 2002
First Named Inventor Slawin M.D., Kevin
Group Art Unit 1645
Examiner Name Unknown

RECEIVED
JAN 28 2003
TECH CENTER 160012900

Sheet 1 of 3

Attorney Docket No: 675.002US1

US PATENT DOCUMENTS

Examiner Initial*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
<i>[Handwritten]</i>	US-5,993,388	11/30/1999	Kattan, M. W., et al	600	300	06/25/1998
<i>[Handwritten]</i>	US-6,409,664	06/25/2002	Kattan, M. W., et al	600	300	11/24/1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	I ²
<i>[Handwritten]</i>	WO-00/63841	10/26/2000	Wilkinson, L.	G06T	11/00	
<i>[Handwritten]</i>	WO-99/38011	07/29/1999	Pollack, M. N., et al	G01N	33/574	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
<i>[Handwritten]</i>		"Human IL- sR Immunoassay, For the quantitative determination of human Interleukin 6 soluble Receptor (IL-6 sR) concentrations in cell culture supemate, serum, plasma, and urine", Quantikine, Catalog Number DR600, pp. 1-15	<i>[Handwritten]</i> 1/99 1999
<i>[Handwritten]</i>		"Human IL-6 Immunoassay, For the quantitative determination of human interleukin 6 (IL-6) concentrations in cell culture supernate, serum, and plasma", Quantikine, Catalog Number D6050, pp. 1-15	<i>[Handwritten]</i> JAN 1999
<i>[Handwritten]</i>		ADLER, H.L., et al., "Elevated Levels of Circulating Interleukin-6 and Transforming Growth Factor-β1 in Patients with Metastatic Prostatic Carcinoma", The Journal of Urology, 161, (January, 1999), pp. 182-187	
<i>[Handwritten]</i>		AKIMOTO, S., et al., "Relationship Between Serum Levels of Interleukin-6, Tumor Necrosis Factor-α and Bone Turnover Markers in Prostate Cancer Patients", Endocrine Journal, Vol. 45, No. 2, (1998), pp. 183-189	
<i>[Handwritten]</i>		BELLUCO, C., et al., "Interleukin-6 Blood Level Is Associated With Circulating Carcinoembryonic Antigen and Prognosis in Patients With Colorectal Cancer", Annals of Surgical Oncology, Vol. 7, No. 1, (March, 2000), pp. 133-138	
<i>[Handwritten]</i>		FIGUEROA, J.A., et al., "Differential Expression of Insulin-Like Growth Factor Binding Proteins in High Versus Low Gleason Score Prostate Cancer", The Journal of Urology, 159, (April, 1998), pp. 1379-1383	
<i>[Handwritten]</i>		IVANOVIC, V., et al., "Elevated plasma levels of TGF- β1 in patients with invasive prostate cancer", Nature Medicine, Vol. 1, No. 4, (April 4, 1995), pp. 282-283	
<i>[Handwritten]</i>		JUNKER, U., et al., "Transforming Growth Factor Beta 1 is Significantly Elevated in Plasma of Patients Suffering From Renal Cell Carcinoma", Cytokine, Vol. 8, No. 10, (October, 1996), pp. 794-798	
<i>[Handwritten]</i>		KAKEHI, Y., et al., "Serum TGF-β1 Levels in Patients with Prostatic Cancer: Positive Correlation with Metastasis and Inverse Correlation with Age", Proceedings of the American Urological Association, Vol. 155, abstract 435, (May, 1996), 1 page	

EXAMINER *[Handwritten Signature]*

DATE CONSIDERED 7/15/02

Substitute Disclosure Statement Form (PTO-1449)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin M.D., Kevin
Group Art Unit	1645
Examiner Name	Unknown

TECH CENTER 1600/2900

JAN 28 2003

RECEIVED

Sheet 2 of 3

Attorney Docket No: 675.002US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
LJM		KATTAN, M.W., et al., "A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer", <u>Journal of the National Cancer Institute</u> , Vol. 90, No. 10, (May 20, 1998), pp. 766-771	
		KONG, FENG-MING, et al., "Elevated Plasma Transforming Growth Factor- β_1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor", <u>Ann. Surg.</u> , Vol. 222, No. 2, (1995), pp. 155-162	
		KRASAGAKIS, K., et al., "Elevated plasma levels of transforming growth factor (TGF)- β_1 and TGF- β_2 in patients with desmethylated malignant melanoma", <u>British Journal of Cancer</u> , Vol. 77, No. 9, (1998), pp. 1492-1494	
		LANGE, I., et al., "Plasma-TGF- β_1 -Konzentrationen bei Patienten mit einem Prostatakarzinom oder einer benignen Prostatahyperplasie", <u>Der Urologe</u> , Vol. 37, (1998), pp. 199-202	With English Abstract
		NAKASHIMA, J., et al., "Serum Interleukin 6 as a Prognostic Factor in Patients with Prostate Cancer", <u>Clinical Cancer Research</u> , 6, (July, 2000), pp. 2702-2706	
		PERRY, K.T., et al., "Transforming Growth Factor Beta as a Clinical Biomarker for Prostate Cancer", <u>Urology</u> , Vol. 49, No. 1, (1997), pp. 151-155	
		SCAMBIA, G., et al., "Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer", <u>British Journal of Cancer</u> , (1995), pp. 354-356	
		SHARIAT, S.F., et al., "Association of Preoperative Plasma Levels of Insulin-Like Growth Factor I and Insulin-Like Growth Factor Binding Proteins-2 and -3 with Prostate Cancer Invasion, Progression, and Metastasis", <u>Journal of Clinical Oncology</u> , 20, (February 1, 2002), pp. 833-841	
		SHARIAT, S.F., et al., "Plasma Levels of Interleukin-6 and Its Soluble Receptor are Associated with Prostate Cancer Progression and Metastasis", <u>Urology</u> , 58, (2001), pp. 1008-1015	
		SHARIAT, S.F., et al., "Preoperative Plasma Levels of Transforming Growth Factor β_1 (TGF- β_1) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy", <u>Journal of Clinical Oncology</u> , 19, (June 1, 2001), pp. 2856-2864	With Abstract
		SHIM, K.S., et al., "Elevated Serum Levels of Transforming Growth Factor- β_1 in Patients with Colorectal Carcinoma", <u>American Cancer Society</u> , (1999), pp. 554-561	
		SMITH, D.S., et al., "Longitudinal Screening for Prostate Cancer with Prostate-Specific Antigen", <u>JAMA</u> , Vol. 276, No. 16, (October, 1996), pp. 1309-1315	
		TSUSHIMA, H., et al., "High Levels of Transforming Growth Factor β_1 in Patients With Colorectal Cancer: Association With Disease Progression", <u>Gastroenterology</u> , Vol. 110, No. 2, (1996), pp. 375-382	
		UEDA, T., et al., "Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis", <u>J Gastroenterol</u> , Vol. 29, (1994), pp. 423-429	
		WIKSTROM, P., et al., "Transforming Growth Factor beta1 is Associated with	

EXAMINER

[Signature]

DATE CONSIDERED

7/15/05


Substitute Disclosure Statement Form (PTO-1449)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

BEST AVAILABLE COPY

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Sheet 3 of 3

Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin M.D., Kevin
Group Art Unit	1645
Examiner Name	Unknown

Attorney Docket No: 675.002US1

RECEIVED
 JAN 28 2003
 TECH CENTER 1600/2800

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>AS</i>		Angiogenesis, Metastasis, and Poor Clinical Outcome in Prostate Cancer", <u>The Prostate</u> , 37, (1998), pp. 19-29	
<i>AS</i>		WOLFF, J.M., et al., "Serum Concentrations of Transforming Growth Factor- β 1 in Patients with Benign and Malignant Prostatic Diseases", <u>Anticancer Research</u> , Vol. 19, (1999), pp. 2657-2659	
<i>AS</i>		WOLFF, J.M., et al., "Transforming growth factor-beta 1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia", <u>Br. J. Urol.</u> , Vol. 81, abstract, (1998), 1 page	
<i>AS</i>		WUNDERLICH, H., et al., "Serum Transforming Growth Factor- β 1 in Patients with Renal Cell Carcinoma", <u>The Journal of Urology</u> , Vol. 157, (May, 1997), pp. 1602-1603	

EXAMINER *AS*

DATE CONSIDERED *7/15/05*

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 1. Applicant is to place a check mark here if English language Translation is attached

BEST AVAILABLE COPY

015 100
MAY 21 2004
PATENT & TRADEMARK

PTO/SB089(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

<i>Complete if Known</i>	
Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin, Kevin
Group Art Unit	1645
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 675.002US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
<i>[Signature]</i>	WO 02/31209A	04/18/2002	Mousses, S., et al.	C12Q	1/68	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume+issue number(s), publisher, city and/or country where published.	T ²
<i>[Signature]</i>		BOK, R. A., et al., "Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of outcome in Hormone-Refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study", <u>Cancer Research</u> , 61(6), (March 15, 2001), pp. 2533-2536	
<i>[Signature]</i>		DUQUE, J. L., et al., "Plasma Levels of Vascular Endothelial Growth Factor are Increased in Patients with metastatic Prostate Cancer", <u>Urology</u> , 54(3), (September 1999), pp. 523-527	
<i>[Signature]</i>		GEORGE, D. J., et al., "Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-Refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480", <u>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</u> , 7(7), (July 2001), pp. 1932-1936	
<i>[Signature]</i>		JONES, A., et al., "Elevated Serum Vascular Endothelial Growth Factor in Patients with Hormone-Escaped Prostate Cancer", <u>BJU International</u> , 85(3), (February 2000), pp. 276-280	

EXAMINER

[Signature]

DATE CONSIDERED

7/15/05

Substitute Disclosure Statement Form (PTO-1449)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached